Background: Breast cancer is a major public health problem with significant morbidity andrnmortality in women worldwide. Studies in Sub-Saharan Africa (SSA) have shown that thernestimated 5-year survival in women with breast cancer is below 50%, which is significantlyrnlower than those from developed countries. There is limited data on survival of patients treatedrnfor breast cancer in Ethiopia. rn rnObjective: The aim of this study is to asses the five-year survival of breast cancer patientsrntreated at Oncology Department of Tikur Anbessa Specialized Hospital (TASH). rn rnMethods: This is a retrospective cohort study that asses the survival of and contributing factorsrnof patients that were evaluated and treated at TASH between September 2014 and August 2015rnG.C. Data was extracted from patient file by data collectors under the supervision of the primaryrninvestigator using structured questionnaire. Patients and/or their relatives were contacted throughrnphone call and for those patients who were not available over the phone, the last date of followrnup was used to calculate overall survival (OS). The data was analyzed using SPSS 22 software. rn rnResults: Out of a total of 249 patient charts collected based on HMIS data, 216 cases were foundrneligible for our study. On further evaluation of the 216 cases, only 181 patients were eligible forrnthe final analysis as 35 patients had some data missing (error of date entry on excel) or were lostrnfrom follow up by more than 6 months and couldnâ€™t be contacted over the phone. rn rnThe mean age of presentation was 43 (SD) years. Most patients (38.1%) had a stage III disease atrnpresentation followed by stage IV disease 31.5%. Only 4.4% of our patients were stage I. rnThe median survival was 27 months where the 5-year OS was 44.2%. Stage at diagnosis,rnduration before the initiation of Adjuvant chemotherapy, number of chemotherapy cycles, thernuse of hormonal therapy and its duration were significantly associated with survival. rn rnConclusion/recommendation: The outcome of stage III & IV patients in our study is very lowrnby the western standards. rn rnWe should devise a policy to increase public awareness, so that we can get these patients at anrnearlier stage. In addition, we have to increase access to recent treatment modalities and expandrnthe available cancer centers.